Journal of Neural Transmission

, Volume 118, Issue 5, pp 683–689

TAR-DNA binding protein-43 and alterations in the hippocampus

  • Tuomas Rauramaa
  • Maria Pikkarainen
  • Elisabet Englund
  • Paul G. Ince
  • Kurt Jellinger
  • Anders Paetau
  • Irina Alafuzoff
Dementias - Original Article


Immunocytochemistry for transactive response binding protein-43 (TDP43) was assessed in the granular cell layer of the dentate gyrus in 250 cases displaying hippocampal pathology identified by haematoxylin–eosin staining. 18%, nearly one in five displayed TDP43 immunoreactive pathology in the granular cell layer of hippocampus. This percentage increased to 43% when only subjects with hippocampal pathology other than vascular in origin were included. When only subjects with severe Alzheimer’s disease-related pathology were included, 42% displayed TDP43-immunoreactive pathology, increasing to 60% when concomitant Alzheimer’s disease and α-synuclein pathology were present. Within this setting, TDP43-immunoreactive pathology was observed to be present in 6% of subjects with hippocampal pathology but without any cognitive impairment. Our findings justify assessment of TDP43 pathology in every case where a pathological alteration is observed in the hippocampus using a routine stain.


TAR-DNA binding protein-43 Hyperphosphorylated-τ p62 Immunohistochemistry Post-mortem Hippocampal alterations 


  1. Alafuzoff I, Helisalmi S, Mannermaa A, Riekkinen P Sr, Soininen H (1999) Beta-amyloid load is not influenced by the severity of cardiovascular disease in aged and demented patients. Stroke 30:613–618Google Scholar
  2. Alafuzoff I, Arzberger T, Al-Sarraj S et al (2008) Staging of neurofibrillary pathology in Alzheimer’s disease: a study of the BrainNet Europe Consortium. Brain Pathol 18:484–496PubMedGoogle Scholar
  3. Alafuzoff I, Thal DR, Arzberger T et al (2009a) Assessment of β-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathol 117:309–320PubMedCrossRefGoogle Scholar
  4. Alafuzoff I, Ince PG, Arzberger T et al (2009b) Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol 117:635–652PubMedCrossRefGoogle Scholar
  5. Amador-Ortiz C, Lin WL, Ahmed Z et al (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol 61:435–445PubMedCrossRefGoogle Scholar
  6. Arai T, Hasegawa M, Akiyama H et al (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602–611PubMedCrossRefGoogle Scholar
  7. Arai T, Mackenzie IR, Hasegawa M et al (2009) Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol 117:125–136PubMedCrossRefGoogle Scholar
  8. Braak H, Alafuzoff I, Arzberger T et al (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–404PubMedCrossRefGoogle Scholar
  9. Chen-Plotkin AS, Lee VM, Trojanowski JQ (2010) TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol 6(4):211–220PubMedCrossRefGoogle Scholar
  10. Freeman SH, Spires-Jones T, Hyman BT et al (2008) TAR-DNA binding protein 43 in Pick disease. J Neuropathol Exp Neurol 67:62–67PubMedCrossRefGoogle Scholar
  11. Fujishiro H, Uchikado H, Arai T et al (2009) Accumulation of phosphorylated TDP-43 in brains of patients with argyrophilic grain disease. Acta Neuropathol 117:151–158PubMedCrossRefGoogle Scholar
  12. Geser F, Lee VM, Trojanowski JQ (2010) Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. Neuropathology 30(2):103–112PubMedCrossRefGoogle Scholar
  13. Hatanpää KJ, Bigio EH, Cairns NJ et al (2008) TAR DNA-binding protein 43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a midwest-southwest consortium for FTLD study. J Neuropathol Exp Neurol 67:271–279PubMedCrossRefGoogle Scholar
  14. Higashi S, Iseki E, Yamamoto R et al (2007) Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer’s disease and dementia with Lewy bodies. Brain Res 1184:284–294PubMedCrossRefGoogle Scholar
  15. Hu WT, Josephs KA, Knopman DS et al (2008) Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol 116:215–220PubMedCrossRefGoogle Scholar
  16. Josephs KA, Holton JL, Rossor MN et al (2004) Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathol Appl Neurobiol 30:369–373PubMedCrossRefGoogle Scholar
  17. Josephs KA, Whitwell JL, Knopman DS et al (2008) Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 70:1850–1857PubMedCrossRefGoogle Scholar
  18. Kadokura A, Yamazaki T, Lemere CA et al (2009) Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. Neuropathology 29:566–573PubMedCrossRefGoogle Scholar
  19. Kuusisto E, Parkkinen L, Alafuzoff I (2003) Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 62:1241–1253PubMedGoogle Scholar
  20. Kuusisto E, Kauppinen T, Alafuzoff I (2008) Use of p62/SQSTM1 antibodies for neuropathological diagnosis. Neuropathol Appl Neurobiol 34:169–180PubMedCrossRefGoogle Scholar
  21. Mackenzie IR, Neumann M, Bigio EH et al (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119:1–4PubMedCrossRefGoogle Scholar
  22. Mateen FJ, Josephs KA (2009) TDP-43 is not present in brain tissue of patients with schizophrenia. Schizophr Res 108:297–298PubMedCrossRefGoogle Scholar
  23. McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944PubMedGoogle Scholar
  24. Nakashima-Yasuda H, Uryu K, Robinson J et al (2007) Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 114:221–229PubMedCrossRefGoogle Scholar
  25. Nelson PT, Abner EL, Schmitt FA et al (2010) Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol 20:66–79PubMedCrossRefGoogle Scholar
  26. Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133PubMedCrossRefGoogle Scholar
  27. Parkkinen L, Soininen H, Laakso M et al (2001) Alpha-synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol 27:314–325PubMedCrossRefGoogle Scholar
  28. Paulson HL (2009) The spinocerebellar ataxias. J Neuroophthalmol 29:227–237PubMedGoogle Scholar
  29. Tolnay M, Clavaguera F (2004) Argyrophilic grain disease: a late-onset dementia with distinctive features among tauopathies. Neuropathology 24:269–283PubMedCrossRefGoogle Scholar
  30. Uryu K, Nakashima-Yasuda H, Forman MS et al (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 67:555–564PubMedCrossRefGoogle Scholar
  31. Wang HY, Wang IF, Bose J, Shen CK (2004) Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics 83:130–139PubMedCrossRefGoogle Scholar
  32. Williams DR, Lees AJ (2009) Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 8:270–279PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Tuomas Rauramaa
    • 1
    • 2
  • Maria Pikkarainen
    • 3
  • Elisabet Englund
    • 4
  • Paul G. Ince
    • 5
  • Kurt Jellinger
    • 6
  • Anders Paetau
    • 7
  • Irina Alafuzoff
    • 1
    • 3
    • 8
  1. 1.Department of PathologyKuopio University HospitalKuopioFinland
  2. 2.Institute of Clinical Medicine, Unit of PathologyUniversity of Eastern FinlandKuopioFinland
  3. 3.Institute of Clinical Medicine, Unit of Neurology, Section of NeuropathologyUniversity of Eastern FinlandKuopioFinland
  4. 4.Department of PathologyUniversity HospitalLundSweden
  5. 5.Department of NeurosciencesUniversity of SheffieldSheffieldUK
  6. 6.Institute of Clinical NeurobiologyViennaAustria
  7. 7.Department of PathologyUniversity of HelsinkiHelsinkiFinland
  8. 8.Department of Genetics and Pathology, Rudbeck LaboratoryUppsala University, Uppsala University HospitalUppsalaSweden

Personalised recommendations